{"filing":{"accession_number":"0001104659-26-092025","cik":"0001661059","ticker":"NXTC","company_name":"NextCure, Inc.","form":"8-K","filing_date":"2026-08-06","report_date":"2026-08-06","primary_document":"nxtc-20260806x8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1661059/000110465926092025/nxtc-20260806x8k.htm"},"events":[{"id":25438,"run_id":23090,"accession_number":"0001104659-26-092025","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.75,"summary":"The Item 2.02 disclosure announces Q2 2026 financial results for the quarter ended June 30, 2026, with detailed metrics including cash position ($20.1M), R\u0026D expenses ($7.4M), G\u0026A expenses ($2.6M), asset impairment charges ($5.1M), and net loss ($14.9M). However, the press release is dominated by the announcement of a proposed merger with Avere Therapeutics and related restructuring activities, which materially overshadows the routine quarterly results disclosure. While this is technically an earnings release, the merger announcement (an M\u0026A activity) is the primary material event driving the filing.","company_name":"NextCure, Inc.","ticker":"NXTC","filing_date":"2026-08-06","form":"8-K","submitted_at":null,"items":[{"id":26268,"accession_number":"0001104659-26-092025","item_number":"2.02","item_title":"Results of Operations and Financial Condition","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.75,"reasoning":"The Item 2.02 disclosure announces Q2 2026 financial results for the quarter ended June 30, 2026, with detailed metrics including cash position ($20.1M), R\u0026D expenses ($7.4M), G\u0026A expenses ($2.6M), asset impairment charges ($5.1M), and net loss ($14.9M). However, the press release is dominated by the announcement of a proposed merger with Avere Therapeutics and related restructuring activities, which materially overshadows the routine quarterly results disclosure. While this is technically an earnings release, the merger announcement (an M\u0026A activity) is the primary material event driving the filing.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-08T02:41:50.226699+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":26268,"accession_number":"0001104659-26-092025","item_number":"2.02","item_title":"Results of Operations and Financial Condition","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.75,"reasoning":"The Item 2.02 disclosure announces Q2 2026 financial results for the quarter ended June 30, 2026, with detailed metrics including cash position ($20.1M), R\u0026D expenses ($7.4M), G\u0026A expenses ($2.6M), asset impairment charges ($5.1M), and net loss ($14.9M). However, the press release is dominated by the announcement of a proposed merger with Avere Therapeutics and related restructuring activities, which materially overshadows the routine quarterly results disclosure. While this is technically an earnings release, the merger announcement (an M\u0026A activity) is the primary material event driving the filing.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-08T02:41:50.226699+00:00","company_name":"NextCure, Inc.","ticker":"NXTC","filing_date":"2026-08-06"}]}